The limited efficacy and intolerable toxicities reported in these studies emphasize the urgent need for stratifying biomarkers for the upfront selection of CRC patients who could potentially benefit from Hsp90 inhibitor therapy. The gene discussed is HSP90AB1; the disease is colorectal carcinoma.